Bevacizumab plus xelox as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer

被引：0
|
作者：
Gruenberger, Thomas
Tamandl, Dietmar
Herbst, Friedrich
Scheithauer, Werner
Zielinski, Christoph
Gruenberger, Birgit
机构：
[1] Med Univ Vienna, Dept Gen Surg, Hepatobiliary Serv, Vienna, Austria
[2] Med Univ Vienna, Dept Oncol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [1] Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
    Gruenberger, T.
    Tamandl, D.
    Puhalla, H.
    Scheithauer, W.
    Zielinski, C.
    Gruenberger, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Neoadjuvant bevacizumab plus XELOX is feasible in patients with potentially curable metastatic colorectal cancer receiving synchronous resection
    Gruenberger, B.
    Scheithauer, W.
    Tamandl, D.
    Zielinski, C.
    Schueller, J.
    Gruenberger, T.
    EJC SUPPLEMENTS, 2007, 5 (04): : 255 - 255
  • [3] Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
    Gruenberger, Brigit
    Tamandl, Dietmar
    Schueller, Johannes
    Scheithauer, Werner
    Zielinski, Christoph
    Herbst, Friedrich
    Gruenberger, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1830 - 1835
  • [4] Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer
    Gruenberger, B.
    Scheithauer, W.
    Tamandl, D.
    Puhalla, H.
    Kornek, G.
    Zielinski, C.
    Gruenberger, T.
    ANNALS OF ONCOLOGY, 2006, 17 : 39 - 40
  • [5] Effectivity of neoadjuvant chemotherapy including bevacizumab in patients with potentially curable metastatic colorectal cancer
    Gruenberger, B.
    Scheithauer, W.
    Tamandi, D.
    Zielinski, C.
    Schueller, J.
    Gruenberger, T.
    ANNALS OF ONCOLOGY, 2007, 18 : VII76 - VII76
  • [6] Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer.
    Gruenberger, B.
    Scheithauer, W.
    Tamandl, D.
    Puhalla, H.
    Kornek, G.
    Zielinski, C.
    Gruenberger, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [7] Progression-free survival in a phase II study of perioperative bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer
    Gruenberger, T.
    Kaczirek, K.
    Bergmann, M.
    Zielinski, C. C.
    Gruenberger, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Progression-free survival in a phase II study of perioperative Bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer Abstracts
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2008, 1 : 1 - 26
  • [10] Efficacy and tolerance of XELOX plus bevacizumab as first line therapy in Moroccan patients with metastatic colorectal cancer
    Tarik, Mahfoud
    Mohamed Reda, Khmamouche
    Rachid, Tanz
    Hassan, Errihani
    Mohamed, Ichou
    ANNALS OF ONCOLOGY, 2017, 28
12345